CAJ | 학술논문

目的：分析替罗非班在急性 ST 段抬高型心肌梗死患者经皮冠状动脉介入治疗（PCI）中的应用效果。方法选取我院2011年1月-2014年1月收治的急性 ST 段抬高型心肌梗死患者98例，随机分为对照组48例和观察组50例。两组患者入院后均给予常规药物治疗和 PCI，观察组患者在此基础上给予替罗非班。观察两组患者术后即刻TIMI 血流改善率、ST 段回落率，术后48 h 主要心血管不良事件（MACE）发生率、出血事件发生率，术后6个月左室射血分数（LVEF）。结果观察组患者术后即刻 TIMI 血流改善率、ST 段回落率高于对照组（P <0.05）；两组患者术后48 h MACE 发生率、出血事件发生率、术后6个月 LVEF 比较，差异均无统计学意义（P >0.05）。结论在急性 ST段抬高型心肌梗死患者 PCI 中应用替罗非班安全有效，其可有效改善患者 TIMI 血流及心肌灌注，且并不增加 MACE、出血事件发生风险。
목적：분석체라비반재급성 ST 단태고형심기경사환자경피관상동맥개입치료（PCI）중적응용효과。방법선취아원2011년1월-2014년1월수치적급성 ST 단태고형심기경사환자98례，수궤분위대조조48례화관찰조50례。량조환자입원후균급여상규약물치료화 PCI，관찰조환자재차기출상급여체라비반。관찰량조환자술후즉각TIMI 혈류개선솔、ST 단회락솔，술후48 h 주요심혈관불량사건（MACE）발생솔、출혈사건발생솔，술후6개월좌실사혈분수（LVEF）。결과관찰조환자술후즉각 TIMI 혈류개선솔、ST 단회락솔고우대조조（P <0.05）；량조환자술후48 h MACE 발생솔、출혈사건발생솔、술후6개월 LVEF 비교，차이균무통계학의의（P >0.05）。결론재급성 ST단태고형심기경사환자 PCI 중응용체라비반안전유효，기가유효개선환자 TIMI 혈류급심기관주，차병불증가 MACE、출혈사건발생풍험。
Objective To analyze the application effect of tirofiban on percutaneous coronary intervention(PCI) in patients with acute ST - segment elevation myocardial infarction. Methods From January 2011 to January 2014,a total of 98 patients with acute ST - elevation myocardial infarction in our hospital were selected and randomly divided into control group(n =48)and observation group( n = 50). Both groups given routine treatment and PCI,observation group given extra tirofiban. TIMI blood flow improvement rate after operation,ST - elevation fall back rate,incidence of major adverse cardiac events (MACE)after operation,incidence of hemorrhage,left ventricular ejection fraction(LEVF)after 6 months of operation be-tween the two groups were compared. Results TIMI blood flow improvement rate after operation and ST - elevation fall back rate of observation group were higher than those of control group(P < 0. 05),while there was no significant differences of incidence of MACE after operation,incidence of hemorrhage,LEVF after 6 months of operation between the two groups( P > 0. 05). Conclusion Tirofiban is effective and safe in PCI in patients with acute ST - segment myocardial infarction,which can improve the TIMI blood flow and myocardial perfusion,without increasing the risk of MACE and hemorrhage.